Mark Hopman Biography and Net Worth

Insider of Beta Bionics

Mark brings over 22 years of healthcare experience to Beta Bionics where he leads commercialization efforts. A seven year veteran of Dexcom, Mark was instrumental in conceiving and building Dexcom’s pharmacy efforts from 2014-2021. Mark is a registered pharmacist in Ohio where he first practiced after graduating pharmacy school from The Ohio State University. He also has his MBA from Xavier University in Cincinnati Ohio.

What is Mark Hopman's net worth?: The estimated net worth of Mark Hopman is at least $1.46 million as of December 4th, 2025. Hopman owns 136,216 shares of Beta Bionics stock worth more than $1,460,917 as of March 21st. This net worth estimate does not reflect any other investments that Hopman may own. Learn More about Mark Hopman's net worth.
How do I contact Mark Hopman?: The corporate mailing address for Hopman and other Beta Bionics executives is 11 HUGHES, IRVINE, CA, 92618. Beta Bionics can also be reached via phone at (949) 427-7785 and via email at [email protected]. Learn More on Mark Hopman's contact information.
Has Mark Hopman been buying or selling shares of Beta Bionics?: During the last ninety days, Mark Hopman has sold $14,392.45 of Beta Bionics stock. Most recently, Mark Hopman sold 353 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $11.57, for a transaction totalling $4,084.21. Following the completion of the sale, the insider now directly owns 139,133 shares of the company's stock, valued at $1,609,768.81. Learn More on Mark Hopman's trading history.
Who are Beta Bionics' active insiders?: Beta Bionics' insider roster includes Stephen Feider (CFO), Mark Hopman (Insider), Mike Mensinger (Insider), and Steven Russell (Insider). Learn More on Beta Bionics' active insiders.
Are insiders buying or selling shares of Beta Bionics?: In the last twelve months, insiders at the sold shares 31 times. They sold a total of 117,369 shares worth more than $2,608,090.96. The most recent insider tranaction occured on March, 4th when insider Mark Hopman sold 353 shares worth more than $4,084.21. Learn More about insider trades at Beta Bionics.
Information on this page was last updated on 3/4/2026.

Mark Hopman Insider Trading History at Beta Bionics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2026	Sell	353	$11.57	$4,084.21	139,133
3/2/2026	Sell	834	$12.36	$10,308.24	139,486
12/4/2025	Sell	2,061	$30.66	$63,190.26	136,216
12/2/2025	Sell	856	$29.34	$25,115.04	138,277
9/5/2025	Sell	11,411	$20.56	$234,610.16	31,215
9/4/2025	Sell	6,818	$19.97	$136,155.46	31,215
9/2/2025	Sell	848	$18.86	$15,993.28	33,284
8/19/2025	Sell	16,158	$16.61	$268,384.38	34,132
6/2/2025	Sell	868	$17.89	$15,528.52	34,132

Mark Hopman Buying and Selling Activity at Beta Bionics

Beta Bionics Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Today's Range

Now: $10.73

$10.50

$10.93

50 Day Range

MA: $13.70

$10.11

$18.50

2 Week Range

Now: $10.73

$8.89

$32.71

Volume

1,714,172 shs

Average Volume

1,076,763 shs

Market Capitalization

$475.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

5.6